Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurotech InternationalNTILF 34 3-1 Month Momentum % is N/A% as of Aug. 18, 2026. GuruFocus rates NTILF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,387 Biotechnology companies, Neurotech International ranks better than 91.71% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-18), Neurotech International's 3-1 Month Momentum % is N/A%.
The industry rank for Neurotech International's 3-1 Month Momentum % or its related term are showing as below:
NTILF's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -7.61 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Neurotech International (OTCPK:NTILF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Neurotech International 3-1 Month Momentum % Related Terms
NTILF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Neurotech International's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurotech International 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neurotech International's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Neurotech International's 3-1 Month Momentum % falls into.
Neurotech International (OTCPK:NTILF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurotech International (NTILF) has a 3-1 Month Momentum % of N/A% as of Aug. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Neurotech International and its competitors. According to the industry distribution chart, Neurotech International ranks #115 out of 1387 companies in the Biotechnology industry, placing it in the top 8.3%.
Is Neurotech International's 3-1 Month Momentum % too high?
Neurotech International's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Neurotech International ranks #115 out of 1387 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neurotech International has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Neurotech International's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurotech International ranks #115 out of 1387 companies for 3-1 Month Momentum %. This places Neurotech International in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Neurotech International and its competitors. Neurotech International's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (NTILF) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Neurotech International's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Neurotech International (NTILF), the current 3-1 Month Momentum % is N/A% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
34GF Score
Get the complete analysis for NTILF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTILF has been successfully added to your 
